Evidence map›Paper›PMID 36315333›Full record

ArticleDigestive diseases and sciences2023

The Frequency of Germline BRCA and Non-BRCA HR-Gene-Variants in a Cohort of Pancreatic Cancer Patients.

M Baz, V Gondran-Teiller, B Bressac, O Cabaret, A Fievet, M Dimaria, V Goldbarg, C Colas, M N Bonnet-Dupeyron, J Tinat and 16 more

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Biallelic GermlineInternational journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 17 institutions in 2 countries.

M BazDépartement d'Oncogénétique, Hôpital Saint Louis, APHP, Paris, France. maria.baz.baz@hotmail.com.ORCID http://orcid.org/0000-0002-9750-9895
V Gondran-TeillerService de Génétique des Tumeurs, Gustave Roussy, Villejuif, France.
B BressacService de Génétique des Tumeurs, Gustave Roussy, Villejuif, France.
O CabaretService Oncogénétique, Gustave Roussy, Villejuif, France.
A FievetService Oncogénétique, Gustave Roussy, Villejuif, France.
M DimariaService Oncogénétique, Gustave Roussy, Villejuif, France.
V GoldbargService Oncogénétique, Gustave Roussy, Villejuif, France.
C ColasDépartement de Génétique (Department of Genetics), Institut Curie, Paris, France.
M N Bonnet-DupeyronDepartment of Genetics, Valence Hospital's Center, Valence, France.
J TinatService de Génétique Médicale, Unité d'Oncogénétique, Centre Hospitalier, Universitaire de Bordeaux, Bordeaux, France.
M LebrunCHU Saint Etienne, Genetic Service, Hôpital de Nord, Saint Etienne, France.
V MariCentre Antoine Lacassagne, CLCC, Unité d'Oncogénétique, Nice, France.
J M LimacherGenetics Department, Hôpitaux Civils de Colmar, Colmar, France.
C CorsiniDepartment of Cancer Genetics, CHU Montpellier, Univ Montpellier, Montpellier, France.
E GinglingerCH de Mulhouse, Service de Génétique, Mulhouse, France.
J C SaurinDepartment of Endoscopy and Gastroenterology, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France.
A BrahimiDepartment of Clinical Genetics, CHU Lille, 59000, Lille, France.
C RouzierUniversité Côte d'Azur, CHU de Nice, INSERM, CNRS, IRCAN, Nice, France.
S GiraudService de Génétique Clinique, Centre Hospitalier Lyon-Sud, Lyon, France.
H SchusterService d'Oncogénétique, CLCC Paul Strauss, Strasbourg, France.
A HollebecqueDépartement de Médecine Oncologique, Gustave Roussy, Villejuif, France.
V BoigeDépartement de Médecine Oncologique, Gustave Roussy, Villejuif, France.
E CauchinInstitut de Cancérologie de l'Ouest René Gauducheau, Saint-Herblain, Nantes, France.
D MalkaDépartement de Médecine Oncologique, Gustave Roussy, Villejuif, France.
O CaronService Oncogénétique, Gustave Roussy, Villejuif, France.
E RouleauService de Génétique des Tumeurs, Gustave Roussy, Villejuif, France.
Institut Gustave Roussy · FRUniversité Paris-Saclay · FRAssistance Publique – Hôpitaux de Paris · FRCentre Antoine Lacassagne · FRCentre Hospitalier de Mulhouse · FRCentre Hospitalier de Valence · FRCentre Hospitalier Universitaire de Bordeaux · FRCentre Hospitalier Universitaire de Lille · FRCentre National de la Recherche Scientifique · FRHôpital Lyon Sud · FRHôpital Nord · FRHopitaux Civils de Colmar · FRHospices Civils de Lyon · FRInstitut Curie · FRInstitut de Cancérologie de l'Ouest · FRLevi Strauss (United States) · USUniversité de Montpellier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Germline DNA alterations affecting homologous recombination pathway genes have been associated with pancreatic cancer (PC) risk. BRCA2 is the most studied gene and affects the management of PC patients and their families. Even though recent reports have suggested a similar role of germline ATM pathogenic variants (PV) in familial PC, there is still a disagreement between experts on how it could affect patient management given the lack of proper PC risk estimates. We retrospectively analyzed the germline data of 257 PC patients among whom nearly 50% were sporadic cases. We showed similar frequencies of BRCA2 (4.9%) and ATM (4.4%) PV or likely pathogenic variants, which were not related to familial history. Based on our findings and that of the literature, we suggest including ATM gene among the panel of genes analyzed in PC patients pending the publication of prospective studies.

Indexed as

Genetic Predisposition to DiseasePancreatic NeoplasmsGerm-Line MutationHumansProspective StudiesRetrospective StudiesGermline DNAHereditary cancerHomologous recombination pathwayNext generation sequencingPancreatic cancer

Identifiers

PMID36315333
OpenAlexW4307776636

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.